Scholarlink

Objective <p>Radioactive iodine therapy (RIT) for Graves’ disease (GD) often involves antithyroid drugs (ATDs) withdrawal and the exacerbation of thyrotoxicosis. This study investigated the efficacy of RIT with concomitant ATDs (CATD) versus temporary ATDs withdrawal in Japanese patients with GD, a population with high iodine intake according to global standards.</p> Results <p>This retrospective observational study included 179 patients with GD who visited the University of Tsukuba Hospital. Propensity score matching (balancing age, sex, thyroid weight, free T4) created comparable groups of 15 patients each: CATD(-) withdrawing ATDs and CATD(+) continuing ATDs during RIT. Cure was defined as hypothyroidism or euthyroidism achieved without ATDs or potassium iodide. Post-matching, the CATD(+) group received significantly higher baseline ATD doses (median 600 vs. 200&#xa0;mg/day propylthiouracil-equivalent; <i>p</i> &lt; 0.008). The cure rate within 12 months after RIT was significantly higher in the CATD(-) group than in the CATD(+) group (<i>n</i> = 12 [80.0%] vs. <i>n</i> = 4 [26.7%]; <i>p</i> = 0.005). CATD may be associated with a lower cure rate within 12 months compared with standard RIT involving temporary ATD discontinuation. We suggest further prospective studies to confirm the efficacy of radioactive iodine therapy with concomitant antithyroid drugs in high iodine intake country.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of radioactive iodine therapy with concomitant antithyroid drugs in Japanese patients with Graves’ disease: a retrospective observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Yoshinori Osaki,
  • Erika Matsuda,
  • Hiroshi Fukazawa,
  • Rikako Nakajima,
  • Takaaki Matsuda,
  • Yuki Murayama,
  • Yoko Sugano,
  • Hitoshi Iwasaki,
  • Motohiro Sekiya,
  • Hitoshi Shimano

摘要

Objective

Radioactive iodine therapy (RIT) for Graves’ disease (GD) often involves antithyroid drugs (ATDs) withdrawal and the exacerbation of thyrotoxicosis. This study investigated the efficacy of RIT with concomitant ATDs (CATD) versus temporary ATDs withdrawal in Japanese patients with GD, a population with high iodine intake according to global standards.

Results

This retrospective observational study included 179 patients with GD who visited the University of Tsukuba Hospital. Propensity score matching (balancing age, sex, thyroid weight, free T4) created comparable groups of 15 patients each: CATD(-) withdrawing ATDs and CATD(+) continuing ATDs during RIT. Cure was defined as hypothyroidism or euthyroidism achieved without ATDs or potassium iodide. Post-matching, the CATD(+) group received significantly higher baseline ATD doses (median 600 vs. 200 mg/day propylthiouracil-equivalent; p < 0.008). The cure rate within 12 months after RIT was significantly higher in the CATD(-) group than in the CATD(+) group (n = 12 [80.0%] vs. n = 4 [26.7%]; p = 0.005). CATD may be associated with a lower cure rate within 12 months compared with standard RIT involving temporary ATD discontinuation. We suggest further prospective studies to confirm the efficacy of radioactive iodine therapy with concomitant antithyroid drugs in high iodine intake country.